Thymoglobulin (ATG) to Preserve Beta Cell Function in New Onset Type 1 Diabetes - MED - PEDS - Endocrinology, University of Minnesota

Return to: Department of Pediatrics : Medical School : Academic Health Center : U of M Home

Gold University of Minnesota M. Skip to main content.University of Minnesota. MyU | One Stop | Directories | Search U of M  
Driven to Discover.
What's Inside

Peds Endocrinology Home
University Pediatrics Foundation Make a Gift
Vikings Children's Fund
Children's Cancer Research Fund
OPs Administrative Center

  Home > Research Patient Opportunities > Type 1 Diabetes (TrialNet) > Thymoglobulin (ATG) to Preserve Beta Cell Function in New Onset Type 1 Diabetes
 

Thymoglobulin (ATG) to Preserve Beta Cell Function in New Onset Type 1 Diabetes

The purpose of this study is to prevent the progression of type 1 diabetes in those with new onset type 1 diabetes (less than 12 weeks after diagnosis). Age is 12-35. Patients are randomly assigned to receive infusions of antithymocyte globulin or a placebo. There is no cost for study participation.

 

Contact Person: Carrie Gibson, RN, BSN
Phone: 612-624-5958
Toll Free: 800-688-5252 ext. 45958
Email: gibso002@umn.edu

Feedback | Notice of Privacy Practices


©2007-2009 Regents of the University of Minnesota. All rights reserved. Contact U of M | Privacy
The University of Minnesota is an equal opportunity educator and employer. Last modified on November 10, 2009